ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0007093;mitotic cell cycle checkpoint;7.0;0.7140352122741334;0.7079369713942671;9.0094850440859;132.2042645947957;5.142344639450834;0.0044247577598742595;0.6138991092621975;[BRCA1, KNTC1, TOPBP1, MSH6, MSH2, BLM, NAE1, BUB1, TGFB1, PLK2, CDC6, ZWINT, WEE1]
GO:0007098;centrosome cycle;4.0;1.0;0.75;9.628524252492122;37.692070457630365;6.088194173566533;0.0012615196775557923;0.5613505331661754;[PPP1R12A, HEPACAM2, TUBE1, BRCA1, UXT, NUP62]
GO:1990090;cellular response to nerve growth factor stimulus;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;97.48528473772916;5.9928839937622085;0.003262744749111514;0.6295966787287501;[CALCA, E2F1, AKT1, ID1]
GO:0000733;DNA strand renaturation;7.0;0.9326813400603323;0.8172600352873667;9.584072489921288;172.76820112826425;7.57984905034425;0.005782396210476689;0.738553198190834;[SMARCAL1, BLM, RAD54L]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, ECM1, CD40, BRCA1, CDH5, C3AR1, CTSH, CYP1B1, ITGB8, CD34, GHSR, ANXA1, ANXA3, GAB1, SIRT1, SFRP2, IL1B, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, TWIST1, PTGS2, DLL1, THBS1, CXCR2, PLCG1, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0110032;positive regulation of G2/MI transition of meiotic cell cycle;9.0;1.0;0.896240625180289;9.628524252492122;414.4836470731219;8.67846133901236;0.013872394656472954;0.8400575416471059;[CDC25A]
GO:0071373;cellular response to luteinizing hormone stimulus;8.0;1.0;0.875;9.628524252492122;601.1788189541068;8.67846133901236;0.020120914044583264;0.8188169164668168;[CCNA2, LHCGR]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[SPI1, EHMT2, SLA2, PHB2, MYB, HOXA2, HOXA7, MEF2A, MEF2C, HOXB4, HOXB3, ATF3, GATA3, PRDM16, ELANE, JUN, PKIG, EZH2, PAWR, PAX5, SIRT1, PAX2, AES, MMP12, BTAF1, FLNA, NR1H2, LGR4, GMNN, TNF, DACH1, MEN1, TLE4, FOXO1, NACC2, WFS1, NFKB1, BCL6, CIITA, FASLG, HHEX, EMILIN1, RFC1, PEG3, XCL1, RBBP8, E2F1, E2F7, PRRX1, KLF8, KLF5, DNAJA3, UXT, ZNF608, EDNRB, DPF3, SOX4, RUNX2, EREG, SFRP2, IFI27, TWIST1, PCBP3, EGR1, BCL11A, ID1, IFNA2, PTPRK, BRCA1, XPO1, CD36, CBFA2T3, MDFIC, IL1B, ARID4A, LOXL2, CHCHD3, BASP1, CCNE1, CALCA, TGFB1, CBX4, CAV1, HMGA1, NR4A2, BMP2, NR4A3, MXD1, CREBZF, HMGB2, MYOCD, IFNG, ELF3, FBP1, PFDN5, MEIS2]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPI1, SPIB, AKT1, MEF2A, MEF2C, PADI2, ATF3, GATA3, JUN, JAG1, JUP, COL1A1, HOXC10, FOS, SIRT1, MMP12, STAT4, ATAD2, PSMC6, PSMC2, LGR4, CCNT2, RUVBL2, ADCYAP1, BLM, FOXO1, NFKB1, CXCL10, CIITA, HHEX, PPP1R12A, PEG3, E2F1, E2F2, E2F5, E2F7, PRRX1, POU2AF1, CCNH, TNFSF11, SFRP2, EGR1, EGR2, EGR3, CD28, CD40, BRCA1, BRCA2, CD3D, RGMA, IL1B, YAP1, IL17A, CD86, CD80, CCNE1, HMGA1, INHBA, IL6, BMP2, TCF4, HMGB2, ARHGEF10L, NUP62, MYOCD, CCNA2, PSRC1, ELF3, CREB5, TAF9, EGF, MAPK14, CD4, RAN, EHF, MYB, HOXA3, HOXA2, HOXA7, HOXA5, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB5, NUP85, PRDM16, NKX2-3, NFE2, FZD5, TGFB1I1, PAX5, PAX2, ENG, EPCAM, NR1H2, GTF2H1, PF4, PLXND1, TNF, CDH1, MEN1, MAP2K2, F2R, COPS5, MAFF, CYR61, LBH, EMILIN1, RFC1, CHUK, SMARCD3, CEBPE, ABLIM3, KLF1, KLF5, CHEK1, RPS6KA1, DPF3, SOX4, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, TWIST1, NHLH2, BCL11B, LIF, IFNA2, PRL, RHOG, MDFIC, TLR4, TLR2, LILRB1, GRHL2, CAMK4, ARID4A, ARID4B, HOXA11, HOXA10, ADRB2, NLRP3, TGFB2, TGFB1, NR4A2, NFKBIA, NR4A1, NR4A3, SLC40A1, CKAP2, DCN, DNM2, DLL1, LUM, MEIS2, MEIS1, RBMX]
GO:0044320;cellular response to leptin stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;109.38485831558611;7.379178354882098;0.003661012767841448;0.7004918368257019;[CCNA2, PID1, NR4A3]
GO:0071930;negative regulation of transcription involved in G1/S transition of mitotic cell cycle;11.0;1.0;0.9324289523296623;9.628524252492122;1849.0626671205805;8.67846133901236;0.061886463420164586;0.8762458687964789;[E2F1, E2F7]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2, TNFAIP3, FASLG, BRCA1, TNFRSF10B, SFRP2]
GO:0036120;cellular response to platelet-derived growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.781341354126479;0.003262744749111514;0.6699184248047958;[PDGFRB, CCNA2, PDGFD, FYN]
GO:0008631;intrinsic apoptotic signaling pathway in response to oxidative stress;7.0;0.8653626801206646;0.7836007053175329;9.523163736834295;52.930841574252625;6.943860283624253;0.001771547632825523;0.7060287030842711;[MELK, CYP1B1]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CDKN1A, BCL2A1, BRCA1, BRCA2, TNF, PYCARD, E2F1, SFN, MLH1, TNFRSF1B, SIRT1, MSH6, MSH2, EPHA2]
GO:0007265;Ras protein signal transduction;7.0;0.7586651285174919;0.7302519295159464;8.935377071932177;27.526979089716047;4.2636448815154875;9.213032174599934E-4;0.5689623627776663;[CYFIP1, CELSR1, EPS8, GRAP2, ARHGDIA, ARHGDIB, RAB32, DOK3, AGTR1, IQGAP3, JUN, HACE1, PLK2, DHCR24, BCL6, LAT, CDKN1A, ARHGAP6, ARHGAP4, RAC2, CHUK, RHOG, RHOH, RAB33B, CCNA2, RHOU, RAB21, PAK1, PDPN, EPS8L1]
GO:0000077;DNA damage checkpoint;8.0;0.811012628672052;0.780506314336026;9.456673995565463;85.75736069739153;5.486614186532078;0.002870221685927797;0.655585704652903;[BLM, CHEK1, E2F1, TOPBP1, MAPK14, MSH6, MSH2]
GO:0072332;intrinsic apoptotic signaling pathway by p53 class mediator;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;80.0523555558605;5.734022359845919;0.002679280298012042;0.64415753539903;[CDKN1A, BRCA2, PYCARD, TP53BP2, E2F1, E2F2, SIRT1, MSH2, JMY]
GO:0048255;mRNA stabilization;10.0;0.8933024483968273;0.861892236059334;9.577230958104572;1968.7172834448895;6.088194173566533;0.06589119574637584;0.7265915450270957;[SLC11A1, AXIN2, MAPK14, E2F1, MYD88]
GO:0000070;mitotic sister chromatid segregation;6.0;1.0;0.8231203125901445;9.628524252492122;56.84344269090966;6.311337724880743;0.0019024988710876387;0.6458824173477649;[MIS12, SMC1A, TUBG1, SMC4, ZWINT, RAN]
GO:0033762;response to glucagon;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;6.166155715036245;0.0024778305216419678;0.6662568552797195;[ARG1, ABCB4, GLP2R, CCNA2, ADCY9, PRKAR1B, PRKAR2B, CYC1, PRKACB]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[CDKN1A, PCNA, C5AR1, ATIC, TGFB1, ANXA3, SULF2, TGFBR3, NFKBIA, CCNA2, CXCL12, NR4A3, EZH2]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[EHMT2, BRCA1, UXT, CHEK1, RBBP8, E2F1, RAD51, EZH2]
GO:0071922;regulation of cohesin loading;9.0;0.7586651285174919;0.775573189439035;9.446202695698167;97.41872309218135;8.16763571524637;0.0032605169907366205;0.8139338954918922;[CDCA5]
GO:0043009;chordate embryonic development;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;22.496195207419138;4.623782033182691;7.529274083310655E-4;0.5595807407949613;[PDGFRA, TPM1, MSH2, TWIST1, GATA3, EPB41L5, PLCG1, EIF2S2, BMP2, MAFF, PTPRR, BRCA1, TMEM100, HHEX, TIE1]
GO:0007076;mitotic chromosome condensation;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;40.5466901453896;7.004484905440688;0.0013570612295141678;0.7332096838060964;[CDCA5, SMC4, SMC2, NCAPD2, NCAPD3]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[CHEK1, SLBP, BLM, BARD1, CDC6, POLA1, POLA2, NASP, MCM7, BRCA1, CHAF1B, CHAF1A, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, RMI1, DBF4, MCM3, MCM4, MCM6, MCM2, POLD1, RBBP8, RPA1, RAD50, POLE2, RPA3, DNAJA3, SSBP1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, PHB2, CYP1B1, EPHB1, SOX4, MEF2C, EREG, SFRP4, SFRP2, SPINT1, BTK, GATA3, INPP5D, SFN, LYN, JUN, BCL11B, FZD5, LIF, CDC6, NOX4, CDKN1A, TNFRSF13B, TGFB1I1, PRL, PTPRK, BRCA2, LRRC32, CTLA4, CD33, HAVCR2, DUSP1, ARG1, PAWR, PDCD1LG2, CBFA2T3, CEACAM1, IL1B, TLR2, PTGS2, PAK1, GPNMB, FRZB, PDPN, CCL23, CDKN2C, LILRB1, LILRB2, PODN, FABP7, PKN1, CD86, CD80, SIRPG, TNF, CDH5, DACH1, MEN1, F2R, TPM1, TSC2, ADCYAP1, HGS, CD274, CUL5, FBLN1, CNN1, NACC2, IGFBP7, TGFB2, TGFB1, RARRES3, CAV2, CAV1, HMGA1, DHCR24, INHBA, IL6, BMP2, BCL6, OGN, TNFAIP3, CXCL1, DUSP10, ADAMTS1, NUP62, PTGIR, MYOCD, AXIN2, TGFBR3, IFNG, LTA, XCL1, PDE5A, DLL1, THBS1, CCL8, E2F1, CCL2, ZNF503, CSK, E2F7, MEIS1, DNAJA3, PMP22, CD9, PTPN6, MNDA, FCGR2B]
GO:0045787;positive regulation of cell cycle;5.0;0.5265193887476639;0.5535007062347522;7.230628979693751;42.184038669436575;3.8238302933926853;0.0014118618110960173;0.4857918708913159;[, CCNH, PHB2, CHEK1, AKT1, SOX4, TAS2R13, FLT3LG, MIF, EREG, BTC, CDCA5, TGFA, RACGAP1, SFN, PLK2, CDC6, CD28, CDKN1A, BRCA1, BRCA2, ANXA1, CIT, RAD51C, IL1B, PCNA, CXCR5, KCNA5, RANBP2, RANBP1, SVIL, CCNT2, CTGF, PDGFRB, CDC25A, CCNE1, TGFB2, TGFB1, UBE2C, NR4A3, CNOT3, NUP62, CCNA2, PSRC1, SMARCD3, E2F1, E2F7, SH2B1, EGF, MEIS2]
GO:1904117;cellular response to vasopressin;8.0;1.0;0.875;9.628524252492122;462.69925393661634;8.67846133901236;0.015486127626965131;0.8188169164668168;[CDC6]
GO:0006303;double-strand break repair via nonhomologous end joining;9.0;0.8933024483968273;0.8428918493787028;9.548481544818586;368.8093148901945;5.8067817141283475;0.012343715862540626;0.693199712083778;[DCLRE1A, BLM, PSMD14, BRCA1, BARD1, MLH1, POLA1, RAD50]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPI1, SPIB, MYB, HOXA3, AKT1, HOXA2, HOXA7, HOXA5, MEF2A, MEF2C, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, GATA3, NKX2-3, JUN, JAG1, JUP, FZD5, HOXC10, PAX5, FOS, SIRT1, PAX2, MMP12, ENG, EPCAM, STAT4, NR1H2, ATAD2, GTF2H1, PSMC6, PSMC2, PF4, CCNT2, PLXND1, TNF, RUVBL2, MEN1, ADCYAP1, FOXO1, NFKB1, CXCL10, COPS5, MAFF, CIITA, CYR61, HHEX, PPP1R12A, CHUK, PEG3, CEBPE, ABLIM3, E2F1, E2F2, E2F5, E2F7, PRRX1, KLF1, KLF5, POU2AF1, CCNH, RPS6KA1, TNFSF11, DPF3, SOX4, SLC11A1, EBF1, FLT3LG, RUNX2, SFRP2, BEX1, TWIST1, NHLH2, EGR1, EGR2, EGR3, BCL11B, LIF, CD28, CD40, PRL, BRCA1, CD3D, RGMA, IL1B, TLR4, TLR2, YAP1, LILRB1, GRHL2, IL17A, ARID4A, ARID4B, HOXA10, ADRB2, NLRP3, TGFB2, TGFB1, HMGA1, INHBA, NR4A2, NFKBIA, NR4A1, IL6, BMP2, NR4A3, TCF4, HMGB2, SLC40A1, ARHGEF10L, MYOCD, CKAP2, DCN, ELF3, TAF9, DLL1, LUM, MAPK14, MEIS2, MEIS1, RBMX]
GO:0006301;postreplication repair;8.0;0.8259837884571596;0.7879918942285797;9.500690880982237;183.0506323445446;5.8067817141283475;0.006126539929698291;0.6719590869034888;[PCNA, BRCA1, POLD3, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, MSH2, POLE2, RPA3]
GO:0006302;double-strand break repair;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;183.0506323445446;4.689477292448085;0.006126539929698291;0.6148200868187911;[DCLRE1A, BRCA1, BRCA2, ESCO2, RAD51C, MSH2, BLM, PSMD14, CDCA5, RAD54B, RBBP8, RAD54L, BARD1, RPA1, MLH1, POLA1, RAD50, RAD51, RPA3]
GO:0071392;cellular response to estradiol stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;338.1710882258028;6.221725566191056;0.011318281988697268;0.6412996473849828;[ABCB4, CCNA2, RUVBL2]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PID1, PTGER2, PTAFR, TNC, P2RY6, E2F1, AKT1, FFAR2, PTGDR, DGAT2, IL1B]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, PDGFD, MYB, PDGFC, E2F1, PDGFRB, PDGFRA, JUN, TGFB1, CDC6, MIF, EREG, BTC, CCNA2, NDUFS4]
GO:0071314;cellular response to cocaine;7.0;1.0;0.8509193652572005;9.628524252492122;537.09778937307;8.67846133901236;0.017976179653688387;0.7947362817240173;[CCNA2]
GO:0071158;positive regulation of cell cycle arrest;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;83.12201169572153;5.395046993006588;0.002782018926502022;0.6268223193749;[CDKN1A, BRCA1, SOX4, PCNA, E2F1, SFN, E2F7, TGFB1, PLK2, CNOT3]
GO:0070345;negative regulation of fat cell proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.87354995152188;8.16763571524637;0.0021377902344145586;0.7408135829017477;[E2F1]
GO:0030521;androgen receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;54.01143535742291;5.948432231191374;0.0018077141342769656;0.6792031009335148;[TGFB1I1, BRCA1, CCNE1, RAN]
GO:0010994;free ubiquitin chain polymerization;7.0;1.0;0.8509193652572005;9.628524252492122;46.126504921393284;8.16763571524637;0.0015438126085597365;0.7686126355688037;[UBE2C]
GO:2000378;negative regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;113.12708673636307;5.905872616772578;0.003786261785297929;0.6251469128630576;[HP, BRCA1, SLC30A10, CD34, CAV1, PAX2]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[RUVBL1, SKP2, CDC25A, CFTR, PSMD14, ADRB2, GATA3, NLRP3, BARD1, NFKBIA, COPS5, TNFAIP3, BRCA1, PSMA5, CCNA2, PSMA6, PSMA3, PSMA4, PSMA2, FAM105A, USP9Y, PSMC6, PSMC2, EIF3F]
GO:0045717;negative regulation of fatty acid biosynthetic process;8.0;0.8436909121759173;0.7968454560879586;9.480104247373848;670.1384648150137;7.138016298065211;0.022428931331895798;0.7400384854347593;[CEACAM1, BRCA1, SIRT1]
GO:0006270;DNA replication initiation;7.0;0.7980440201809971;0.7499413753476991;9.405380701177911;149.0421272461911;6.343086423195323;0.0049883058697239;0.6753050999230941;[MCM7, CDC6, POLA1, POLA2, CCNE1, MCM3, MCM4, MCM6, TOPBP1, MCM2]
GO:1903671;negative regulation of sprouting angiogenesis;9.0;0.8653626801206646;0.8289219652406215;9.456673995565463;200.36531453095495;6.599019797332524;0.00670604676027516;0.7337148045016781;[THBS1, E2F2]
GO:0070979;protein K11-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;6.375876246018314;0.00527474598481953;0.7584915600596062;[UBE2C]
GO:0000729;DNA double-strand break processing;7.0;0.811012628672052;0.7564256795932265;9.35659053700848;149.0421272461911;6.599019797332524;0.0049883058697239;0.6883935445785896;[BARD1, BLM, RAD50, EXO1, RBBP8, BRCA1]
GO:0007088;regulation of mitotic nuclear division;7.0;0.5860072649471136;0.6439229977307573;8.169909229792605;54.97351338155213;4.573066940603674;0.0018399140199305624;0.5847862212690335;[SMC3, PHB2, CHEK1, KNTC1, FBXO5, PDGFRB, EREG, BTC, CCNE1, AURKAIP1, CDCA5, TGFA, PKMYT1, TGFB1, CAV2, UBE2C, CDC6, STAG2, CD28, NUP62, DUSP1, SMC1A, CCNA2, IL1B, BUB1, SH2B1, RANBP2, RANBP1, EGF]
GO:0000724;double-strand break repair via homologous recombination;9.0;0.8653626801206646;0.8289219652406215;9.515195567185119;520.6240308586224;5.299736813202263;0.01742481778162994;0.6672694122704188;[BLM, PSMD14, BRCA1, BRCA2, RAD54B, RBBP8, RAD54L, RPA1, RAD50, RAD51, RAD51C, RPA3]
GO:0007089;traversing start control point of mitotic cell cycle;10.0;1.0;0.9152410118609203;9.628524252492122;354.407431007331;8.390779266560578;0.01186169776983519;0.8443458537639685;[CDC6]
GO:1990314;cellular response to insulin-like growth factor stimulus;8.0;1.0;0.875;9.628524252492122;388.66587636398185;7.57984905034425;0.013008297105323164;0.7626338329336335;[CCNA2, GHSR, TGFB1]
GO:0007080;mitotic metaphase plate congression;7.0;1.0;0.8509193652572005;9.628524252492122;61.63195576956532;6.193554689224359;0.002062766094448262;0.6676580400938822;[SEH1L, CDCA5, NUP62, PSRC1]
GO:0085020;protein K6-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;7.697632086000634;0.00527474598481953;0.8260862151842345;[BARD1, BRCA1]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[IL5RA, SLA2, FGF5, EFEMP1, GRAP2, EPHB1, PDGFRB, PDGFRA, MAP2K2, EREG, BTC, MELK, BTK, EPHA3, EPHA2, BLK, CSF2RB, MAP2K6, LYN, LIF, BMX, CLK4, PTK2, CLK1, ITK, GHR, SYK, FGR, ZAP70, HCK, LCK, KIT, IL3RA, HBEGF, FYN, CSK, IL12RB2, EGF, TIE1, WEE1, PTPN6, TEK]
GO:0030071;regulation of mitotic metaphase/anaphase transition;10.0;0.7586651285174919;0.7945735761196663;9.405380701177911;262.3324330841205;5.885253329569843;0.0087800304514636;0.7162131408273906;[BUB1, DUSP1, UBE2C, CDC6]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[EHF, SPI1, CCNH, SPIB, MYB, HOXA7, HOXA5, SOX4, MEF2A, MEF2C, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, GATA3, NHLH2, EGR1, EGR2, JUN, BCL11B, TGFB1I1, BRCA1, HOXC10, PAX5, FOS, SIRT1, PAX2, FLNA, GTF2H1, GRHL2, CCNT2, ARID4A, HOXA10, C5AR1, HMGA1, NFKB1, COPS5, MAFF, MYOCD, ELF3, CREB5, CEBPE, TAF9, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, PRRX1, MEIS2, MEIS1, KLF5, POU2AF1, RBMX]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, EPHB1, PDGFRB, PDGFRA, MAP2K2, VRK1, MELK, BTK, SIK1, BLK, LYN, BMX, EIF2S1, CLK4, PTK2, CLK1, ITK, LRRK2, MAP4K1, SYK, IRAK3, FGR, ZAP70, HCK, LCK, KIT, PAK1, FYN, CSK, CAMK4, TEK]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CCNH, NR3C2, CTGF, NRBP1, RUNX2, MAZ, NR4A2, NR4A1, NR4A3, TCF4, CDKN1A, MED23, YAP1, TAF9, POLR2E, E2F2, POLR2I, POLR2J, POLR2K, POLR2L, NR1H2, GTF2H1]
GO:0043392;negative regulation of DNA binding;5.0;0.7586651285174919;0.6695735761196662;8.866384200445225;32.533753988449135;5.788089581116195;0.0010888754675157227;0.5862441822128946;[E2F1, JUN, NFKBIA, ID1]
GO:0031398;positive regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;528.4459358446122;5.113634533568402;0.01768660990225356;0.6767525197159333;[LRRK2, PTPN22, BRCA1, SKP2, ADRB2, NDFIP2, WFS1, UBE2C, CAV1]
GO:0071732;cellular response to nitric oxide;6.0;1.0;0.8231203125901445;9.628524252492122;346.50110413771324;7.004484905440688;0.011597080124741305;0.6813299963962409;[CCNA2, FOXO1, DNM2]
GO:0072425;signal transduction involved in G2 DNA damage checkpoint;9.0;0.9326813400603323;0.8625812952104552;9.590783924509275;196.6208089386036;7.292166977892469;0.006580721527935406;0.769162383550154;[CHEK1, BRCA1]
GO:0016572;histone phosphorylation;8.0;0.7090535922965819;0.729526796148291;9.195660170195843;367.80445225036385;6.444869117505266;0.012310084014303157;0.7045909063862833;[VRK1, CCNA2, CHEK1, PKN1]
GO:0010458;exit from mitosis;5.0;1.0;0.7902410118609202;9.628524252492122;29.819065850336454;7.379178354882098;9.980172985937987E-4;0.6676125360964777;[EPS8, UBE2C]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[MPL, PHB2, SLC8A1, AKT1, KCND2, SIRT1, CCNA2, TWIST1, PTGS2, E2F1]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, BRCA1, PTGS2, SULF2, IL1B, C3AR1, CYP1B1]
GO:0010971;positive regulation of G2/M transition of mitotic cell cycle;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;355.9636244052406;6.481236761676141;0.011913782162380092;0.7276913745807394;[SMARCD3, CDC25A, RAD51C]
GO:0045739;positive regulation of DNA repair;8.0;0.7671156992804218;0.7585578496402109;9.360260265897443;499.6181899148078;5.8650506222523235;0.01672177118926996;0.6749389615747303;[BLM, PCNA, BRCA1, SIRT1]
GO:1904385;cellular response to angiotensin;8.0;1.0;0.875;9.628524252492122;462.69925393661634;7.379178354882098;0.015486127626965131;0.7523715242355574;[CDC6, SLC30A10, NFKB1]
GO:0045737;positive regulation of cyclin-dependent protein serine/threonine kinase activity;12.0;0.8933024483968273;0.8947715367885583;9.585964638073326;2922.0785093664276;6.193554689224359;0.09779933800857048;0.7648589874268262;[CCNT2, CCNH, AKT1, CDC6, PSRC1]
GO:0007064;mitotic sister chromatid cohesion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;49.163113097731234;7.212124270218933;0.0016454451514518356;0.6919486831672181;[CDCA5, SMC1A]
GO:1900740;positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;990.0589542238915;6.599019797332524;0.033136382202663156;0.7527151911823093;[TP53BP2, E2F1, SFN]
GO:1904668;positive regulation of ubiquitin protein ligase activity;12.0;1.0;0.9481203125901445;9.628524252492122;754.3373369627636;7.212124270218933;0.025246991808615726;0.8169486831672182;[UBE2C]
GO:0008156;negative regulation of DNA replication;8.0;0.7090535922965819;0.729526796148291;9.223059144383958;828.3435142391211;6.113511981550823;0.02772391196081998;0.6876452870438905;[SMARCAL1, BLM, GMNN, BRCA2, SMC3, CDC6, SMC1A, MSH6, STAG2, MSH2, BCL6]
GO:0071681;cellular response to indole-3-methanol;6.0;1.0;0.8231203125901445;9.628524252492122;467.4090985487011;8.16763571524637;0.01564376188754665;0.7408135829017477;[JUP, CDH1, BRCA1]
GO:0051574;positive regulation of histone H3-K9 methylation;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;804.3299673530898;7.474488534686424;0.02692020015733362;0.8146746435927894;[MYB, BRCA1, SIRT1]
GO:0051572;negative regulation of histone H3-K4 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;804.8473500351352;8.390779266560578;0.026937516490087493;0.8615337942327104;[BRCA1]
GO:0051573;negative regulation of histone H3-K9 methylation;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;805.1350321075869;7.57984905034425;0.026947144950155395;0.8200627852632958;[PAX5, BRCA1, SIRT1]
GO:0051571;positive regulation of histone H3-K4 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;804.0422852806381;7.004484905440688;0.026910571697265715;0.7906386361357586;[MYB, BRCA1]
GO:0031145;anaphase-promoting complex-dependent catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;350.55619955642163;6.221725566191056;0.011732800519056534;0.7334203466557586;[UBE2C]
GO:0070512;positive regulation of histone H4-K20 methylation;11.0;1.0;0.9324289523296623;9.628524252492122;803.63682017253;9.777073627680469;0.02689700114499224;0.9324289523296623;[BRCA1]
GO:0035067;negative regulation of histone acetylation;11.0;0.811012628672052;0.8379352666656883;9.498471124243924;1304.334881216342;6.943860283624253;0.04365491464912905;0.7875382901567328;[SPI1, TWIST1, BRCA1, SIRT1]
GO:0044818;mitotic G2/M transition checkpoint;10.0;0.8933024483968273;0.861892236059334;9.551563211355994;492.819650181817;6.343086423195323;0.016494230182695288;0.7396267465268138;[BLM, CDC6, BRCA1, MSH6, TOPBP1, NAE1]
GO:0000079;regulation of cyclin-dependent protein serine/threonine kinase activity;11.0;0.7866048967936545;0.8257314007264895;9.474373572664863;340.6851601099881;5.181953777545879;0.011402425712143147;0.6974343094988531;[CDKN1A, CCNT2, CCNH, TNFAIP3, HHEX, AKT1, MEN1, MYOCD, CDC25A, CCNA2, PSRC1, CCNE1, BLM, PKMYT1, SFN, CDKN2C, GTF2H1, CDC6]
GO:0006978;DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator;8.0;1.0;0.875;9.628524252492122;145.46952913610525;7.004484905440688;0.004868734226108882;0.7332096838060964;[CDKN1A, BRCA1, BRCA2]
GO:2000617;positive regulation of histone H3-K9 acetylation;12.0;1.0;0.9481203125901445;9.628524252492122;1488.212472397538;7.8311634786251565;0.049809132146875434;0.8486063770733797;[GATA3, BRCA1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[SPI1, EHMT2, SLA2, MYB, HOXA2, HOXA7, MEF2A, MEF2C, HOXB4, HOXB3, ATF3, GATA3, PRDM16, ELANE, JUN, PKIG, EZH2, PAWR, PAX5, SIRT1, AES, MMP12, NR1H2, TNF, DACH1, MEN1, TLE4, FOXO1, NACC2, WFS1, NFKB1, BCL6, CIITA, FASLG, HHEX, RFC1, PEG3, RBBP8, E2F1, E2F7, PRRX1, KLF8, KLF5, DNAJA3, UXT, ZNF608, EDNRB, SOX4, IFI27, TWIST1, PCBP3, EGR1, BCL11A, ID1, XPO1, CD36, IL1B, LOXL2, CHCHD3, CCNE1, TGFB1, CBX4, CAV1, NR4A2, BMP2, NR4A3, MXD1, MYOCD, IFNG, FBP1, MEIS2]
GO:0051984;positive regulation of chromosome segregation;5.0;0.6634067003016617;0.6219443620117511;8.39638057119949;42.06625563378019;6.444869117505266;0.0014079197188904481;0.6198319182472036;[CDC6]
GO:0031536;positive regulation of exit from mitosis;9.0;1.0;0.896240625180289;9.628524252492122;562.0425168150831;8.16763571524637;0.018811057232375368;0.8139338954918922;[TGFB1, UBE2C, CDCA5, PHB2]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, PPP2R1A, SKP2, TUBG1, CDC25A, CIT, DNM2, CCNA2, MELK, PKMYT1, PRKAR2B, WEE1, CDK14]
GO:0006977;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;11.0;1.0;0.9324289523296623;9.628524252492122;888.119660647831;5.75172193694532;0.0297245657860804;0.7265722796674696;[CDKN1A, PCNA, E2F1, SFN, E2F7, SOX4, PLK2, CNOT3]
GO:0000083;regulation of transcription involved in G1/S transition of mitotic cell cycle;10.0;0.8933024483968273;0.861892236059334;9.541512875502493;264.067998117236;6.444869117505266;0.008838118251214853;0.7448319182472036;[PCNA, CDC6, POLA1, CCNE1, E2F1, FBXO5, E2F7]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, MCM7, GMNN, SKP2, CDC25A, DBF4, CCNE1, MCM3, MCM4, RHOU, MCM6, MCM2, CUL5, PRIM1, IQGAP3, RBBP8, RANBP2, RANBP1, CDKN2C, PLK2, RPA1, CDC6, INHBA, POLA1, POLA2, WEE1, NASP, POLE2, RPA3]
GO:0034644;cellular response to UV;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;66.19362175939281;5.420364800990877;0.0022154409498949313;0.628117073252615;[CDKN1A, FMR1, PTPRK, RUVBL2, CHEK1, MME, SIRT1, CDC25A, PCNA, PTGS2, POLD1, EIF2S1, MFAP4]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, BRCA1, PYCARD, TCL1A, AKT1, CHUK, SIRT1, CHI3L1, XCL1, CCL13, CALCA, GATA3, ADAMTS12, THBS1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, CCL21, CCL20, MAPK14, NFKB1, COL1A1]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPN22, PTPRK, DUSP10, DUSP2, DUSP1, DUSP6, CDC25A, TPTE, PTPRE, PTPRC, PTPN6]
GO:0032467;positive regulation of cytokinesis;7.0;0.7043150770688792;0.7030769037916401;9.015419779605713;142.0565341908292;6.193554689224359;0.004754504356786525;0.6676580400938822;[SVIL, CXCR5, TAS2R13, CDC6, CIT, RACGAP1, NUP62]
GO:0051865;protein autoubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;155.4032479663248;5.769740442447999;0.005201206855589802;0.7103058064080809;[BRCA1]
GO:0033314;mitotic DNA replication checkpoint;11.0;1.0;0.9324289523296623;9.628524252492122;738.0966094602528;7.379178354882098;0.02470342927481251;0.8098004765652196;[CDC6, TOPBP1, NAE1]
GO:0070936;protein K48-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;5.8650506222523235;0.00527474598481953;0.7323679139043926;[TNFAIP3, HACE1, UBE2C]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPI1, SPIB, MEF2A, MEF2C, PADI4, ATF3, GATA3, JUN, HACE1, EZH2, HOXC10, CHAF1B, FOS, SIRT1, STAT4, FLNA, ZNF467, ATAD2, PKN1, CCNT2, RUVBL2, RUVBL1, FOXO1, NFKB1, CIITA, FASLG, HHEX, E2F1, E2F5, E2F7, PRRX1, POU2AF1, CCNH, UXT, EREG, BTK, ZNF700, EGR1, EGR2, EGR3, ID1, BRCA1, LOXL2, HMGA1, MXD1, HMGB2, AFF3, NUP62, MYOCD, ELF3, CREB5, TAF9, MAPK14, EHF, PHB2, HOXA9, MYB, HOXA3, HOXA2, HOXA7, HOXA5, HOXA4, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB6, HOXB5, PRDM16, NKX2-3, NFE2, TGFB1I1, ZNF367, BRD2, PAWR, PAX5, PAX2, AES, GTF2H1, MEN1, TLE4, NACC2, MAP2K6, HOPX, COPS5, BCL6, CNOT3, MAFF, LBH, RFC1, SMARCD3, CEBPE, ABLIM3, POLR2E, ZNF503, POLR2I, POLR2J, POLR2K, POLR2L, KLF1, KLF8, KLF5, MNDA, ZNF608, DPF3, SOX4, EBF1, TWIST1, NHLH2, BCL11B, BCL11A, CBFA2T3, MDFIC, GRHL2, ARID4A, ARID4B, HOXA11, HOXA10, CHCHD3, C5AR1, NLRP3, CBX4, NR4A2, CREBZF, KDM5D, LTF, MEIS2, MEIS1, RBMX]
GO:0046600;negative regulation of centriole replication;11.0;0.9326813400603323;0.8987696223598284;9.590783924509275;466.4695881312043;7.697632086000634;0.015612317319377515;0.8260862151842345;[BRCA1]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[TGFB1I1, GATA3, TNF, FOXO1, E2F1, TGFB1, JAG1, SORT1, SIRT1, IL6]
GO:0006633;fatty acid biosynthetic process;8.0;0.6493065804076676;0.6996532902038338;8.912904216080118;359.8485513982277;5.076593261888053;0.01204380717262807;0.6346172154986847;[TECR, BRCA1, ELOVL4, ELOVL6, MIF, ELOVL7, MGST1, PTGS2, CYP3A4, ALOX5, PNPLA8, SCD, NDUFAB1, PLP1]
GO:0006359;regulation of transcription by RNA polymerase III;10.0;0.8436909121759173;0.837086467948879;9.52844079393514;248.56913769389934;6.481236761676141;0.008319385340914571;0.7466917612613706;[BRCA1, BDP1]
GO:0006349;regulation of gene expression by genetic imprinting;7.0;0.8933024483968273;0.7975705894556142;9.577230958104572;130.9317736178294;6.8867018697843045;0.004382168632042727;0.7031056191423581;[KCNQ1, ARID4A, ARID4B, BRCA1]
GO:0044030;regulation of DNA methylation;7.0;0.7980440201809971;0.7499413753476991;9.253830803050711;73.34977914704017;6.7325511899570465;0.0024549510975359675;0.6952223462072524;[SPI1, BRCA1, GRHL2]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, CYP1B1, HOXA5, MEF2C, ATF3, SFN, PLCG1, BARD1, LYN, JUN, NOX4, CTLA4, TIMP3, ANXA1, DUSP1, PAWR, SIRT1, DUSP6, AES, PTGS2, FGD3, FGD4, FRZB, GSN, BIK, G0S2, TNF, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, MAP2K6, TNFRSF10B, BCL6, PLEKHF1, FASLG, CYR61, LCK, NLRC4, CCL5, E2F1, CCL2, P2RX1, MNDA, PPP2R1A, SOX4, SFRP4, SFRP2, IFI27, SIK1, INPP5D, TP53BP2, TNFSF12, ITM2C, CD40, CTSZ, CTSH, VAV1, IL1B, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, CD40LG, PDGFRB, NLRP3, TGFB2, TGFB1, CAV1, INHBA, EIF2S1, IL6, BMP2, NR4A3, JMY, UBE2M, MMP9, DNM2, IFNG, LTA, BCL2A1, THBS1, HSPD1, CNR1, HSPE1, LTBR]
GO:2000620;positive regulation of histone H4-K16 acetylation;13.0;1.0;0.9625549647676366;9.628524252492122;1673.9769773112196;9.083926447120524;0.056026502949136;0.9271073857191605;[BRCA1]
GO:0033147;negative regulation of intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;234.23542340630428;7.138016298065211;0.007839648823214116;0.7400384854347593;[LBH, BRCA1, PHB2]
GO:0071466;cellular response to xenobiotic stimulus;4.0;0.7436939687323844;0.6218469843661922;8.578702127993445;40.79473292833871;5.769740442447999;0.0013653629982354628;0.5450647945471605;[MCM7, ABCB4, SLC8A1, FOXO1, E2F1, EGR1, TGFB1, ARG1, CCNA2]
